| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60f8c64064aa8193284c81612ec434fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba25c936248bc57ded636c5f8744a2a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3a9f1edebbff43738190e37d58865736
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6fd24bc72c6c02a2cd5a5655ae14f7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b1e9c3e8835db3fb0045b1eb62ed0f2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 |
| filingDate |
2012-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ba9088828d1f723233d84008ad20a01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54b0e8b55cdc96a547ece454c27d2aa7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7aa474a32f86c7b42ac974960ed683b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51b201954ff405f3fbbbb99ef2abbb95 |
| publicationDate |
2013-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8546551-B2 |
| titleOfInvention |
Method to detect prostate cancer in a sample |
| abstract |
The present invention provides methods to detect prostate cancer by detecting the RNA encoded by PCA3. The disclosure provides a method for determining a predisposition, or presence of prostate cancer comprising: (a) contacting a sample with at least one oligonucleotide that hybridizes to a PCA3 polynucleotide; (b) detecting an amount of PCA3 and second prostate-specific polynucleotides; and (c) comparing the amount of PCA3 polynucleotide that hybridizes to the oligonucleotide to a predetermined cut off value, and determining the presence or absence of prostate cancer. Diagnostic kits are provided for detecting prostate cancer or the risk of developing same comprising: (a) at least one container means containing at least one oligonucleotide probe or primer that hybridizes to PCA3 (b) at least one oligonucleotide probe or primer that hybridizes with a second prostate specific nucleic acid; and (c) reagents for detecting PCA3 and the second prostate specific nucleic acid. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11104958-B2 |
| priorityDate |
2003-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |